BPH Corporate Limited ACN 95 912 002 PO Box 317, North Perth Western Australia 6906

14 View Street, North Perth Western Australia 6006 admin@biopharmica.com.au www.biopharmica.com.au

T: +61 8 9328 8366 F: +61 8 9328 8733

BPH Corporate [ASX: BPH] ASX Announcement

9 November 2010 Companies Announcements Office Australian Securities Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000

DR ROBIN SCAIFE TO PRESENT AT MELANOMA SYMPOSIUM TODAY BPH Corporate Limited [ASX: BPH] is pleased to attach the presentation that Principal Researcher Dr Robin Scaife has been invited by the Scott Kirkbride Melanoma Research Centre (SKMRC) to give at the Melanoma Symposium in Perth today.

Dr Scaife was recently awarded a highly prestigious discovery grant which is due to start in January 2011. The SKMRC supports research that is aimed at providing crucial breakthroughs for improved diagnosis and treatment of melanomas. Dr Scaife’s presentation details innovative strategies to identify new drug leads to target melanoma cells.

Although melanomas have a reputation for being particularly refractory to therapeutic intervention, some types of melanoma have recently been shown to respond well to a new class of customized cancer drugs. Dr Scaife and his collaborators at Western Australian Institute for Medical Research (WAIMR) and the University of Western Australia are using the high-content imaging and analysis platform at Molecular Discovery Systems to screen a significant new resource of new drug-like molecules for inhibitors of melanoma cell survival and proliferation. Also presenting is Dr Louise Winteringham, who as a direct result of the SKMRC grant has been leading a team at WAIMR investigating the tumor suppressor gene HLS5 and its potential influence in melanoma. Dr Winteringham said “through their research they are showing that HLS5 is targeting one of the pathways in Melanoma”. BPH has been investing in the tumor suppressor gene ‘HLS5’ project since it was reported by WAIMR Director Professor Peter Klinken in 2004. Yours sincerely,

David Breeze Chairman For more information contact: Mr David Breeze, Chairman BPH Corporate Limited Tel : +61 8 9328 8366

Identification of New Drug

Leads to Target Melanoma

Cells

Dr Robin Scaife

Molecular Discovery Systems

WAIMR

Chemotherapies

Progressive

Responsive

(10-15%)

Khan et al., Cancer Control (2006)

Ap

op

tos

isD

rug

eff

lux

Lee et al., PCM Res (2010)

PLX-4032

BRAF V600ET

(80% responsive)

Mitotic Drugs

Jordan et al., Cancer Res (1996)

Nigg, Nature Reviews (2001)

Taxol

Metaphase

Anaphase

Mitotic Arrest

23h

23.5h

24h

24.5h

HeLa1 µ µµµMTaxol

DMSO

1 µ µµµMTaxol

Anti-β-tubulin/GFP-H2B

020

4060

8010

0

14710131619

prem

itosis

mito

sis

x 30minutes

Mitotic Slippage

14.5h

17.5h

24.5h

44h

10 nMTaxol

10 nMTaxol

Anti-β-tubulin/GFP-H2B

020

40

60

80

100

147

10

13

16

19

pre

mit

mitosis1

postm

it1

postm

it2

postm

it3

mitosis2

postm

it4

10 nMTx

x 30min

Exit

Death signalMitotic signal

Time

Death

Induction of Mitotic Death

0

0.2

0.4

0.6

0.81

1.2

E10

Plate 5

Antibody signal

TX+ DMSO

TX+5E10

TX+ DMSO

TX+5E10

GFP-H2B

Apopto

sis

TX+5E10

Cell Line Variation

DLD-1

HT-29

Longley et al., AACR (2006)

Gascoigne et al., Cancer Cell (2008)

Gascoigne et al., Cancer Cell

(2008)

Mitotic signalDeath signal

DLD-1 Time

Death

Exit

SAC-independent death

Huang et al., Cancer Cell (2009)

siRNA

SAC

Cdc20

APC/C

Mitotic Arrest

CyclinB1/CDK1

Spindle drugs

High-content Screening

Apopto

sis

SAC

APC/C

Cdk15E10

APCi

New Melanoma Drug Leads